


## PHARMACEUTICAL 2017

## Ra Pharmaceuticals Inc. Rank 65 of 313





## PHARMACEUTICAL 2017



## Ra Pharmaceuticals Inc. Rank 65 of 313

The relative strengths and weaknesses of Ra Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ra Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 254% points. The greatest weakness of Ra Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 434% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	119,502
Cost of Goods Sold	0
Intangible Assets	445
Liabilities, Current	6,737
Liabilities, Non-Current	0
Other Assets	1,334
Other Compr. Net Income	0
Other Expenses	-18
Other Liabilities	2,859
Other Net Income	-858
Property and Equipment	5,537
Research and Development	27,928
Revenues	4,928
Selling, General and Administrative Expense	5,024

Output Variable	Value in 1000 USD
Assets	126,818
Liabilities	9,596
Expenses	32,934
Stockholders Equity	117,222
Net Income	-28,864
Comprehensive Net Income	-28,864
Economic Capital Ratio	17%